PLoS ONE (Jan 2013)

Identification of small molecule activators of BMP signaling.

  • Karen Vrijens,
  • Wenwei Lin,
  • Jimmy Cui,
  • Dana Farmer,
  • Jonathan Low,
  • Elodie Pronier,
  • Fu-Yue Zeng,
  • Anang A Shelat,
  • Kiplin Guy,
  • Michael R Taylor,
  • Taosheng Chen,
  • Martine F Roussel

DOI
https://doi.org/10.1371/journal.pone.0059045
Journal volume & issue
Vol. 8, no. 3
p. e59045

Abstract

Read online

Bone Morphogenetic Proteins (BMPs) are morphogens that play a major role in regulating development and homeostasis. Although BMPs are used for the treatment of bone and kidney disorders, their clinical use is limited due to the supra-physiological doses required for therapeutic efficacy causing severe side effects. Because recombinant BMPs are expensive to produce, small molecule activators of BMP signaling would be a cost-effective alternative with the added benefit of being potentially more easily deliverable. Here, we report our efforts to identify small molecule activators of BMP signaling. We have developed a cell-based assay to monitor BMP signaling by stably transfecting a BMP-responsive human cervical carcinoma cell line (C33A) with a reporter construct in which the expression of luciferase is driven by a multimerized BMP-responsive element from the Id1 promoter. A BMP-responsive clone C33A-2D2 was used to screen a bioactive library containing ∼5,600 small molecules. We identified four small molecules of the family of flavonoids all of which induced luciferase activity in a dose-dependent manner and ventralized zebrafish embryos. Two of the identified compounds induced Smad1, 5 phosphorylation (P-Smad), Id1 and Id2 expression in a dose-dependent manner demonstrating that our assays identified small molecule activators of BMP signaling.